4.7 Review

Cathepsin C inhibition as a potential treatment strategy in cancer

Journal

BIOCHEMICAL PHARMACOLOGY
Volume 194, Issue -, Pages -

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bcp.2021.114803

Keywords

Protease; Inhibitor; Neutrophil; Treatment strategy; Inflammation; Cancer

Funding

  1. Ministere de l'Enseignement Superieur et de la Recherche
  2. Region Centre Val de Loire (Project PIRANA) [2019-00134916]
  3. Graduate College (Graduiertenkolleg, GRK) of the German Research Society (Deutsche Forschungsgemeinschaft, DFG) [2338]
  4. target validation project for pharmaceutical development ALTERNATIVE of the German Ministry for Education and Research (Bundesministerium fur Bildung und Forschung, BMBF)
  5. German Centre for Lung Research (Deutsches Zentrum fur Lungenforschung, DZL)
  6. Deutsche Forschungsgemeinschaft (DFG) [KE 576/10-1, 394046635 -SFB 1365]

Ask authors/readers for more resources

Cathepsin C plays a crucial role in cancer development and metastasis, and is considered as a potential therapeutic target for various types of cancer. Recent studies have highlighted the important interaction between tumor-associated CatC, NSPs, and NETs in cancer progression, providing new insights for cancer treatment strategies.
Epidemiological studies established an association between chronic inflammation and higher risk of cancer. Inhibition of proteolytic enzymes represents a potential treatment strategy for cancer and prevention of cancer metastasis. Cathepsin C (CatC) is a highly conserved lysosomal cysteine dipeptidyl aminopeptidase required for the activation of pro-inflammatory neutrophil serine proteases (NSPs, elastase, proteinase 3, cathepsin G and NSP-4). NSPs are locally released by activated neutrophils in response to pathogens and non-infectious danger signals. Activated neutrophils also release neutrophil extracellular traps (NETs) that are decorated with several neutrophil proteins, including NSPs. NSPs are not only NETs constituents but also play a role in NET formation and release. Although immune cells harbor large amounts of CatC, additional cell sources for this protease exists. Upregulation of CatC expression was observed in different tissues during carcinogenesis and correlated with metastasis and poor patient survival. Recent mechanistic studies indicated an important interaction of tumorassociated CatC, NSPs, and NETs in cancer development and metastasis and suggested CatC as a therapeutic target in a several cancer types. Cancer cell-derived CatC promotes neutrophil recruitment in the inflammatory tumor microenvironment. Because the clinical consequences of genetic CatC deficiency in humans resulting in the elimination of NSPs are mild, small molecule inhibitors of CatC are assumed as safe drugs to reduce the NSP burden. Brensocatib, a nitrile CatC inhibitor is currently tested in a phase 3 clinical trial as a novel antiinflammatory therapy for patients with bronchiectasis. However, recently developed CatC inhibitors possibly have protective effects beyond inflammation. In this review, we describe the pathophysiological function of CatC and discuss molecular mechanisms substantiating pharmacological CatC inhibition as a potential strategy for cancer treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available